Objective To summarize mechanisms and research progress of bile acid (BA) regulate the immune microenvironment of hepatocellular carcinoma (HCC) through tumor-associated macrophage (TAM). Methods Relevant studies published in China and abroad were reviewed, focusing on altered BA metabolism in HCC, BA receptor-mediated changes in TAM function, immune-cell interactions and therapeutic investigations. Results Alterations in BA synthesis, conjugation and transport, disrupted microbial transformation can change the composition and tissue distribution of BAs in HCC. Different BAs have different functions such as promoting TAM immunosuppression, enhance antitumor macrophage responses. BA can also directly regulate the functions of CD8+ T cells, natural killer T cells and natural killer cells. Interventions such as targeting BA production, targeting specific BA type and its receptor signaling have reduced tumor burden or enhanced immune therapy effect. Phase Ⅱ studies of BA combined with immune checkpoint inhibitors are in progress. Conclusions Altered BA composition regulates the HCC immune microenvironment through both TAM and effector lymphocytes, the role of BA determined by its type, receptor, target cell, and disease context. Related mechaniss and therapeutic strategies require further validation in human-derived models and prospective clinical studies.
Citation：
YANG Xu, XIA Chaosheng, HONG Rongfu, SHI Zhitian, HE Yutao, NI Fan, WANG Lin. The bile acid-macrophage axis in the immune microenvironment of hepatocellular carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2026, 33(9): 1316-1322. doi: 10.7507/1007-9424.202607051
Copy
Copyright ? the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. |
|
| 2. |
|
| 3. |
|
| 4. |
|
| 5. |
|
| 6. |
|
| 7. |
|
| 8. |
|
| 9. |
|
| 10. |
|
| 11. |
|
| 12. |
|
| 13. |
|
| 14. |
|
| 15. |
|
| 16. |
|
| 17. |
Shi G, Xiao Y, Li Z, et al. CD48 is a novel immune checkpoint on tumour-associated macrophages in hepatocellular carcinoma [J/OL]. Gut, 2026: gutjnl-2025-336744. doi: 10.1136/gutjnl-2025-336744.
|
| 18. |
|
| 19. |
|
| 20. |
|
| 21. |
|
| 22. |
|
| 23. |
|
| 24. |
|
| 25. |
|
| 26. |
|
| 27. |
Zhang ZG. Tauroursodeoxycholic acid combined with PD-1/PD-L1 immunotherapy in advanced hepatocellular carcinoma: a prospective study [EB/OL]. (2025-07-15)[2026-09-03]. https://clinicaltrials.gov/study/NCT07064668.
|
| 28. |
Wang P. Tauroursodeoxycholic acid (TUDCA) plus camrelizumab and regorafenib in hepatocellular carcinoma previously treated with anti-PD1/PD-L1 and bevacizumab[EB/OL]. (2025-08-17)[2026-09-03]. https://clinicaltrials.gov/study/NCT07100392.
|
| 29. |
Wang P. A platform trial for personalized and adaptive therapies in hepatocellular carcinoma [EB/OL]. (2026-04-21)[2026-09-03]. https://clinicaltrials.gov/study/NCT07328009.
|
| 30. |
|
| 31. |
|
| 32. |
|
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17. Shi G, Xiao Y, Li Z, et al. CD48 is a novel immune checkpoint on tumour-associated macrophages in hepatocellular carcinoma [J/OL]. Gut, 2026: gutjnl-2025-336744. doi: 10.1136/gutjnl-2025-336744.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27. Zhang ZG. Tauroursodeoxycholic acid combined with PD-1/PD-L1 immunotherapy in advanced hepatocellular carcinoma: a prospective study [EB/OL]. (2025-07-15)[2026-09-03]. https://clinicaltrials.gov/study/NCT07064668.
- 28. Wang P. Tauroursodeoxycholic acid (TUDCA) plus camrelizumab and regorafenib in hepatocellular carcinoma previously treated with anti-PD1/PD-L1 and bevacizumab[EB/OL]. (2025-08-17)[2026-09-03]. https://clinicaltrials.gov/study/NCT07100392.
- 29. Wang P. A platform trial for personalized and adaptive therapies in hepatocellular carcinoma [EB/OL]. (2026-04-21)[2026-09-03]. https://clinicaltrials.gov/study/NCT07328009.
- 30.
- 31.
- 32.
1/5
WeChat